Compare PKE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | ZURA |
|---|---|---|
| Founded | 1954 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.2M | 521.8M |
| IPO Year | 1994 | N/A |
| Metric | PKE | ZURA |
|---|---|---|
| Price | $30.39 | $5.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 235.6K | ★ 550.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $79.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.41 | $0.99 |
| 52 Week High | $29.85 | $7.25 |
| Indicator | PKE | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 44.10 |
| Support Level | $17.99 | $5.49 |
| Resistance Level | N/A | $5.75 |
| Average True Range (ATR) | 1.30 | 0.47 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 82.55 | 40.16 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.